Ignite Creation Date:
2025-12-24 @ 9:19 PM
Ignite Modification Date:
2026-01-02 @ 4:37 AM
Study NCT ID:
NCT02713204
Status:
COMPLETED
Last Update Posted:
2019-05-07
First Post:
2016-03-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
Sponsor:
Regeneron Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-03-31
Start Date Type:
ACTUAL
Primary Completion Date:
2017-10-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-10-03
Completion Date Type:
ACTUAL
First Submit Date:
2016-03-14
First Submit QC Date:
None
Study First Post Date:
2016-03-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-10-03
Results First Submit QC Date:
None
Results First Post Date:
2019-05-07
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-05-01
Last Update Post Date:
2019-05-07
Last Update Post Date Type:
ACTUAL